Related Experiment Videos
Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy.
A H MacLennan1, A MacLennan, S O'Neill
1Department of Obstetrics and Gynaecology, University of Adelaide, SA.
The Medical Journal of Australia
|August 3, 1992
Summary
This study found that a hormone replacement therapy regimen of conjugated equine estrogens and medroxyprogesterone acetate is safe and effective for postmenopausal women, significantly reducing menopausal symptoms with manageable side effects.
Area of Science:
- Endocrinology
- Gynecology
- Women's Health
Background:
- Postmenopausal hormone replacement therapy (HRT) is used to manage symptoms.
- Continuous conjugated equine estrogens (CEE) and cyclical medroxyprogesterone acetate (MPA) is a common HRT regimen.
Purpose of the Study:
- To evaluate the effectiveness and safety of a specific CEE and MPA regimen.
- To assess the incidence of side effects and clinical outcomes in postmenopausal women.
Main Methods:
- A six-month, prospective, open-label study involving 76 postmenopausal women.
- The regimen included 0.625 mg CEE and 10 mg MPA for the first 14 days of each month.
- Outcomes measured included menopausal symptom scores, lipid profiles, endometrial histology, and bleeding patterns.
Main Results:
- Significant reductions in menopausal symptom scores (54% at 3 months, 62% at 6 months).
- Endometrial biopsies showed atrophic or secretory endometrium, with no hyperplasia.
- Total and LDL cholesterol decreased significantly; HDL remained unchanged; triglycerides increased within normal limits.
- Minor side effects were common but largely resolved with dose adjustment.
Conclusions:
- The CEE and MPA regimen is a safe and effective option for postmenopausal symptom management.
- Early follow-up and dose titration can effectively manage initial side effects.
- This HRT regimen demonstrates favorable effects on menopausal symptoms and lipid profiles.